Human serum albumin-free stabilized interferon liquid formulations

Details for Australian Patent Application No. 2004233603 (hide)

Owner Ares Trading S.A.

Inventors Samaritani, Fabrizio; Del Rio, Alessandra

Agent Griffith Hack

Pub. Number AU-B-2004233603

PCT Pub. Number WO2004/096263

Priority 60/530,169 17.12.03 US; 03101210.7 01.05.03 EP

Filing date 29 April 2004

Wipo publication date 11 November 2004

Acceptance publication date 26 February 2009

International Classifications

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 47/12 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carboxylic acids

A61K 47/18 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K 47/26 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carbohydrates

Event Publications

20 October 2005 PCT application entered the National Phase

  PCT publication WO2004/096263 Priority application(s): WO2004/096263

26 February 2009 Application Accepted

  Published as AU-B-2004233603

25 June 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004233606-Pellet formulations of acid-labile antiulcer benzimidazole compounds

2004233601-Intravenous injection of non-neurotoxic plasminogen activators for the treating of stroke